record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
Velammal et al. 2025 (Child's Nervous System systematic review, n=40 pediatric patients)
authors
reviewer:will-blair
Oncolytic virotherapy (HSV G-207, DNX-2401, adenovirus) shows clinical signals in pediatric HGG with median OS 4.1-47.7 months and manageable toxicity, not standard in adult GBM.
vs_a8a3b3dc0a24b41b · manual_curation
outgoing
vf_31924c9845d4dc97Both oncolytic virotherapy and BAC regimens address recurrent glioma; pediatric data lacking for BAC, suggesting orphan drug gap in pHGG trials
events
vev_b5c50264c03cc18afinding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_e79ee4d92e5f622cfinding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.